Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018 - ResearchAndMarkets.com

DUBLIN--()--The "Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012- 2018 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.

There has been a long standing willingness for parties to enter licensing deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages. Licensing is a specific type of partnering deal whereby the parties to the deal agree to commercialize a compound, product or technology.

There are several forms of licensing deal. Traditional licensing arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subsequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaboration on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the licensing agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

Other forms of licensing such as sub-licensing and cross-licensing are also explored, with examples provided together with listing of recent deals in pharma, biotech and diagnostics.

The report provides a detailed understand and analysis of how and why companies enter licensing deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing deal making

Chapter 3 - Overview of licensing deal structure

Chapter 4 - Leading licensing deals

Chapter 5 - Top 50 most active licensing dealmakers

Chapter 6 - Licensing deal term financials

Chapter 7 - Licensing contract directory since 2012

Appendices

Appendix 1 - Licensing dealmaking by companies A-Z

Appendix 2 - Licensing dealmaking by industry sector

Appendix 3 - Licensing dealmaking by stage of development

Appendix 4 - Licensing dealmaking by therapy area

Appendix 5 - Licensing dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/research/hl2t56/global_licensing?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Pharmaceuticals, Diagnostics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Pharmaceuticals, Diagnostics